Increasing interest in real-world evidence (RWE) across all stakeholder groups has the industry buzzing about its current role in clinical trials and the potential impact of expanded use.
Will 2020 be the year the UK harnesses the potential of its health data, as seven new national ‘data hubs' start to break down data silos and embrace real world evidence?
Although real world evidence (RWE) is a hot topic in pharma right now, many still question whether it is acceptable to be used in regulatory decision making.
Ahead of the eyeforpharma Awards we spoke to judge Jennifer Wong – AstraZeneca’s senior director, RWE strategy & alliances, global medical affairs – about why collaboration and RWE
Between genomic data, electronic health records and digital health tools, we have all the information we need to transform the fortunes of people living with cancer – but how do we ensure i
A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.